Published in Trends Mol Med on April 09, 2008
Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal (2010) 1.59
The vitamin nicotinamide: translating nutrition into clinical care. Molecules (2009) 1.36
Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy. Hum Mol Genet (2012) 1.36
The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration. J Clin Invest (2010) 1.35
FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci (2014) 1.32
A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev (2009) 1.31
Highly phosphorylated FOXO3A is an adverse prognostic factor in acute myeloid leukemia. Clin Cancer Res (2010) 1.30
FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene (2011) 1.24
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. Channels (Austin) (2009) 1.21
Ligand-independent phosphorylation of the glucocorticoid receptor integrates cellular stress pathways with nuclear receptor signaling. Mol Cell Biol (2011) 1.19
SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets (2012) 1.14
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Erythropoietin and oxidative stress. Curr Neurovasc Res (2008) 1.07
Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer (2012) 1.06
Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res (2010) 1.06
Clever cancer strategies with FoxO transcription factors. Cell Cycle (2008) 1.05
Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol (2010) 1.04
Mammalian target of rapamycin signaling in diabetic cardiovascular disease. Cardiovasc Diabetol (2012) 1.04
Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) (2012) 1.04
The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol (2009) 1.04
Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res (2011) 1.04
Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res (2008) 1.03
Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol (2011) 1.02
EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res (2011) 1.01
The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res (2009) 1.01
FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol (2010) 1.00
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma. Blood (2013) 1.00
FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) (2009) 0.99
Foxo1, a novel regulator of osteoblast differentiation and skeletogenesis. J Biol Chem (2010) 0.99
New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev (2010) 0.98
Signaling of reactive oxygen and nitrogen species in Diabetes mellitus. Oxid Med Cell Longev (2010) 0.97
DAF-16/Forkhead box O transcription factor: many paths to a single Fork(head) in the road. Antioxid Redox Signal (2010) 0.97
Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95
Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci (2012) 0.94
New Insights for Oxidative Stress and Diabetes Mellitus. Oxid Med Cell Longev (2015) 0.94
Novel applications of trophic factors, Wnt and WISP for neuronal repair and regeneration in metabolic disease. Neural Regen Res (2015) 0.94
Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res (2010) 0.93
Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol (2011) 0.93
A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev (2010) 0.92
PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One (2012) 0.92
FoxO transcription factors support oxidative stress resistance in human chondrocytes. Arthritis Rheumatol (2014) 0.92
Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol (2012) 0.92
Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal (2010) 0.91
WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res (2013) 0.91
FoxO1 and hepatic lipid metabolism. Curr Opin Lipidol (2009) 0.91
Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal (2009) 0.90
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol (2012) 0.90
The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer. BMC Cancer (2014) 0.90
Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? Expert Opin Ther Targets (2008) 0.90
FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res (2009) 0.90
Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. Curr Neurovasc Res (2013) 0.90
WISP1: Clinical insights for a proliferative and restorative member of the CCN family. Curr Neurovasc Res (2014) 0.88
Novel directions for diabetes mellitus drug discovery. Expert Opin Drug Discov (2012) 0.86
Novel avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol (2010) 0.86
Cutting through the complexities of mTOR for the treatment of stroke. Curr Neurovasc Res (2014) 0.86
FoxO Transcription Factors and Regenerative Pathways in Diabetes Mellitus. Curr Neurovasc Res (2015) 0.85
SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer. World J Stem Cells (2015) 0.84
FoxO proteins in the nervous system. Anal Cell Pathol (Amst) (2015) 0.83
Taking aim at Alzheimer's disease through the mammalian target of rapamycin. Ann Med (2014) 0.82
Therapeutic promise and principles: metabotropic glutamate receptors. Oxid Med Cell Longev (2010) 0.82
MicroRNAs: Allies or foes in erythropoiesis? J Cell Physiol (2012) 0.81
Programming apoptosis and autophagy with novel approaches for diabetes mellitus. Curr Neurovasc Res (2015) 0.81
FoxO-dependent regulation of diacylglycerol kinase α gene expression. Mol Cell Biol (2012) 0.81
Erythropoietin and diabetes mellitus. World J Diabetes (2015) 0.80
Targeting sirtuin-1 in Huntington's disease: rationale and current status. CNS Drugs (2013) 0.79
The FOX transcription factors regulate vascular pathology, diabetes and Tregs. Front Biosci (Schol Ed) (2009) 0.79
Can Tea Consumption be a Safe and Effective Therapy Against Diabetes Mellitus-Induced Neurodegeneration? Curr Neuropharmacol (2014) 0.76
Regeneration in the nervous system with erythropoietin. Front Biosci (Landmark Ed) (2016) 0.76
Role of transcription factor acetylation in the regulation of metabolic homeostasis. Protein Cell (2015) 0.76
Loss of Murine FOXO3 in Cells of the Myeloid Lineage Enhances Myelopoiesis but Protects from K/BxN-Serum Transfer-Induced Arthritis. PLoS One (2015) 0.76
The solution structure of the forkhead box-O DNA binding domain of Brugia malayi DAF-16a. Proteins (2014) 0.76
FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L. Oncotarget (2016) 0.75
Novel effects of Brefeldin A (BFA) in signaling through the insulin receptor (IR) pathway and regulating FoxO1-mediated transcription. Cell Logist (2014) 0.75
PAX3 is a novel tumor suppressor by regulating the activities of major signaling pathways and transcription factor FOXO3a in thyroid cancer. Oncotarget (2016) 0.75
Negative regulation of the FOXO3a transcription factor by mTORC2 induces a pro-survival response following exposure to ultraviolet-B irradiation. Cell Signal (2016) 0.75
Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells. Oncotarget (2017) 0.75
Molecular signaling cascades involved in nonmelanoma skin carcinogenesis. Biochem J (2016) 0.75
Transcription factor HBP1 is a direct anti-cancer target of transcription factor FOXO1 in invasive oral cancer. Oncotarget (2017) 0.75
Disease onset and aging in the world of circular RNAs. J Transl Sci (2016) 0.75
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 17.38
Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature (2001) 14.44
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell (2007) 8.94
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer (2007) 8.05
Dynamic FoxO transcription factors. J Cell Sci (2007) 6.30
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
A conserved MST-FOXO signaling pathway mediates oxidative-stress responses and extends life span. Cell (2006) 5.36
Identification of the differential distribution patterns of mRNAs and consensus binding sequences for mouse DAF-16 homologues. Biochem J (2000) 5.30
Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab (2007) 4.74
Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol (2007) 4.73
Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science (2005) 4.61
Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science (2004) 4.61
Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science (2003) 4.32
Disruption of forkhead transcription factor (FOXO) family members in mice reveals their functional diversification. Proc Natl Acad Sci U S A (2004) 4.25
Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity (2004) 3.98
The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J (2004) 3.92
FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J Biol Chem (2004) 3.39
New avenues of exploration for erythropoietin. JAMA (2005) 3.23
Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat Immunol (2006) 3.21
FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem (2002) 2.90
Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem (2004) 2.72
Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J (2004) 2.50
Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol (2005) 2.44
Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat Med (2005) 2.43
Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation (2002) 2.37
Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev (2005) 2.30
Paclitaxel-induced nuclear translocation of FOXO3a in breast cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res (2006) 2.13
Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol (2007) 1.96
Identification and characterization of members of the FKHR (FOX O) subclass of winged-helix transcription factors in the mouse. Mamm Genome (2001) 1.94
Haplotypes in the human Foxo1a and Foxo3a genes; impact on disease and mortality at old age. Eur J Hum Genet (2007) 1.85
GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest (2006) 1.77
FOXO forkhead transcription factors induce G(2)-M checkpoint in response to oxidative stress. J Biol Chem (2002) 1.76
SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med (2005) 1.73
Expression of the serum- and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types of environmental stress stimuli in mammary epithelial cells. J Biol Chem (2002) 1.72
Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: a novel mechanism related to diabetic kidney disease. J Am Soc Nephrol (2006) 1.71
Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem (2007) 1.60
FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ (2006) 1.59
Protein kinase B-alpha inhibits human pyruvate dehydrogenase kinase-4 gene induction by dexamethasone through inactivation of FOXO transcription factors. Diabetes (2004) 1.58
Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns (2005) 1.52
In control of biology: of mice, men and Foxes. Biochem J (2006) 1.50
Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res (2007) 1.48
Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol (2005) 1.47
Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005) 1.46
Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res (2008) 1.40
Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc Natl Acad Sci U S A (2006) 1.37
Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol (2003) 1.34
Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol (2007) 1.33
Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene (2002) 1.32
Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci (2003) 1.31
Foxo3a induces motoneuron death through the Fas pathway in cooperation with JNK. BMC Neurosci (2004) 1.29
Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide. Curr Med Chem (2006) 1.28
Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development (2007) 1.28
The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab (2004) 1.27
Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res (2005) 1.26
Differential regulation of Foxo3a target genes in erythropoiesis. Mol Cell Biol (2007) 1.26
Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem (2007) 1.25
Down-regulation of manganese-superoxide dismutase through phosphorylation of FOXO3a by Akt in explanted vascular smooth muscle cells from old rats. J Biol Chem (2006) 1.24
Adenovirus-mediated gene transfer of FKHRL1 triple mutant efficiently induces apoptosis in melanoma cells. Cancer Biol Ther (2006) 1.23
Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res (2006) 1.22
Phosphorylation of p66Shc and forkhead proteins mediates Abeta toxicity. J Cell Biol (2005) 1.22
Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res (2007) 1.21
CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med (2004) 1.20
Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol Cell Endocrinol (2007) 1.19
The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res (2005) 1.18
FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J Neurochem (2002) 1.18
Effects of aging and caloric restriction on the gene expression of Foxo1, 3, and 4 (FKHR, FKHRL1, and AFX) in the rat skeletal muscles. Microsc Res Tech (2002) 1.17
Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal (2007) 1.16
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Down-regulation of a forkhead transcription factor, FOXO3a, accelerates cellular senescence in human dermal fibroblasts. J Gerontol A Biol Sci Med Sci (2005) 1.13
"Sly as a FOXO": new paths with Forkhead signaling in the brain. Curr Neurovasc Res (2007) 1.12
Enteric neuroblasts require the phosphatidylinositol 3-kinase/Akt/Forkhead pathway for GDNF-stimulated survival. Mol Cell Neurosci (2005) 1.12
Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res (2006) 1.10
Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Oncogene (2007) 1.06
Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. Fertil Steril (2006) 1.05
Estradiol prevents the focal cerebral ischemic injury-induced decrease of forkhead transcription factors phosphorylation. Neurosci Lett (2006) 1.02
Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin. Endocrinology (2003) 1.01
Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate. Cancer Res (2007) 1.00
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci (2007) 1.00
Inhibition of forkhead box class O family member transcription factors in rheumatoid synovial tissue. Arthritis Rheum (2007) 0.98
The induction of Bim expression in human T-cell blasts is dependent on nonapoptotic Fas/CD95 signaling. Blood (2006) 0.98
The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses. Eur J Immunol (2006) 0.97
Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. Acta Med Okayama (2004) 0.97
Altered FOXO1 transcript levels in peripheral blood mononuclear cells of systemic lupus erythematosus and rheumatoid arthritis patients. Mol Med (2007) 0.93
Latent protein LANA2 from Kaposi's sarcoma-associated herpesvirus interacts with 14-3-3 proteins and inhibits FOXO3a transcription factor. J Virol (2006) 0.89
Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring) (2006) 0.89
Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. J Immunol (2006) 0.87
New avenues of exploration for erythropoietin. JAMA (2005) 3.23
mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med (2012) 1.59
Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res (2007) 1.48
The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther (2008) 1.38
The vitamin nicotinamide: translating nutrition into clinical care. Molecules (2009) 1.36
Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol (2003) 1.34
A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev (2009) 1.31
Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci (2003) 1.31
Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci (2004) 1.30
Cell Life versus cell longevity: the mysteries surrounding the NAD+ precursor nicotinamide. Curr Med Chem (2006) 1.28
Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem (2007) 1.25
Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res (2006) 1.22
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res (2007) 1.21
Vital elements of the Wnt-Frizzled signaling pathway in the nervous system. Curr Neurovasc Res (2005) 1.21
Targeting disease through novel pathways of apoptosis and autophagy. Expert Opin Ther Targets (2012) 1.14
SIRT1: new avenues of discovery for disorders of oxidative stress. Expert Opin Ther Targets (2012) 1.14
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals (2005) 1.13
Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol (2008) 1.13
"Sly as a FOXO": new paths with Forkhead signaling in the brain. Curr Neurovasc Res (2007) 1.12
Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res (2003) 1.10
Erythropoietin and oxidative stress. Curr Neurovasc Res (2008) 1.07
Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res (2010) 1.06
Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci (2004) 1.05
Clever cancer strategies with FoxO transcription factors. Cell Cycle (2008) 1.05
Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol (2010) 1.04
Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res (2011) 1.04
The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol (2009) 1.04
Prevention of β-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) (2012) 1.04
Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res (2011) 1.04
EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res (2011) 1.01
Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res (2005) 1.01
The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res (2009) 1.01
Cardiovascular disease and mTOR signaling. Trends Cardiovasc Med (2011) 1.00
FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol (2010) 1.00
Raves and risks for erythropoietin. Cytokine Growth Factor Rev (2008) 0.99
FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) (2009) 0.99
Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev (2010) 0.98
New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev (2010) 0.98
WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res (2012) 0.95
Erythropoietin: new directions for the nervous system. Int J Mol Sci (2012) 0.95
Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL. Curr Neurovasc Res (2012) 0.95
Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascade. Int J Mol Sci (2012) 0.94
Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res (2010) 0.93
Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol (2011) 0.93
A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev (2010) 0.92
Targeting cardiovascular disease with novel SIRT1 pathways. Future Cardiol (2012) 0.92
PRAS40 is an integral regulatory component of erythropoietin mTOR signaling and cytoprotection. PLoS One (2012) 0.92
Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal (2010) 0.91
WISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1. Curr Neurovasc Res (2013) 0.91
Navigating novel mechanisms of cellular plasticity with the NAD+ precursor and nutrient nicotinamide. Front Biosci (2004) 0.91
Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal (2009) 0.90
Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? Expert Opin Ther Targets (2008) 0.90
A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Future Neurol (2012) 0.90
FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res (2009) 0.90
Tuberous sclerosis protein 2 (TSC2) modulates CCN4 cytoprotection during apoptotic amyloid toxicity in microglia. Curr Neurovasc Res (2013) 0.90
Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia. Curr Neurovasc Res (2012) 0.88
Novel avenues of drug discovery and biomarkers for diabetes mellitus. J Clin Pharmacol (2010) 0.86
Novel directions for diabetes mellitus drug discovery. Expert Opin Drug Discov (2012) 0.86
Nicotinamide: A Nutritional Supplement that Provides Protection Against Neuronal and Vascular Injury. J Med Food (2001) 0.84
Therapeutic promise and principles: metabotropic glutamate receptors. Oxid Med Cell Longev (2010) 0.82
Targeting erythropoietin for chronic neurodegenerative diseases. Expert Opin Ther Targets (2013) 0.80
S100B raises the alert in subarachnoid hemorrhage. Rev Neurosci (2016) 0.76
Diabetes: Implications of a novel point mutation of SIRT1 in T1DM. Nat Rev Endocrinol (2013) 0.76
The Role of HMGB1 in Pial Arteriole Dilating Reactivity following Subarachnoid Hemorrhage in Rats. J Vasc Res (2016) 0.75